A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
NCT07793929
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- End Stage Renal Disease
- Renal Impairment
- Obesity
- Overweight
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Kailera
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Kailera Clinical Site · Orlando, FL
Texas · 1
- Kailera Clinical Site · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.